PIEZO1

Across TCGA pan-cancer cohorts, PIEZO1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PIEZO1 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PIEZO1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PIEZO1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where PIEZO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.452	0.626	.003	43	view →
LSCC	OS	Tertile	II,III,IV	0.543	0.893	.014	18	view →
HNSC	DFS	Median	All	1.000	0.393	.018	14	view →
UCEC	OS	Tertile	II,III,IV	1.000	0.500	.014	4	view →
LUAD	OS	Tertile	II,III,IV	0.879	1.000	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PIEZO1–PDAC (OS)

Open the PDAC breakdown →